Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787487 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
A Phase 2 study of Primary Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 1
- Study location
NCT01787487 is a Phase 2 study of Primary Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 121 participants, roughly in line with the 117-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01787487, a Phase 2 study of Primary Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate and azacytidine may be an effective treatment for myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm.
Conditions Studied
Interventions
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- DRUG Ruxolitinib Phosphate
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2013-03-13 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01787487
The ClinicalTrials.gov registry entry for NCT01787487 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 117-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 3 interventions - of which Azacitidine is the first listed.
NCT01787487 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01787487 about?
NCT01787487 is a clinical study titled "Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm". This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs use...
What is the current status of trial NCT01787487?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2013-03-13. Estimated completion is 2027-04-30.
What conditions does trial NCT01787487 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase.
What interventions are being tested in trial NCT01787487?
The interventions under investigation include: Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Ruxolitinib Phosphate (DRUG).
Who is sponsoring clinical trial NCT01787487?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01787487 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Explore more on PlainTrial
Primary Myelofibrosis
All registered trials for this condition
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.